Ravi Shah MBBS, MD 🇮🇳🇨🇦

765 posts

Ravi Shah MBBS, MD 🇮🇳🇨🇦

Ravi Shah MBBS, MD 🇮🇳🇨🇦

@Cell4Cure

Pediatric Oncologist-BMT physician, alumnus @PSMedCollege @PGIMER @UofC @Harvard passionate about #Cancer #BMT #Immunology #CellTherapy

Calgary, Alberta Katılım Mayıs 2014
659 Takip Edilen513 Takipçiler
Andres Gomez
Andres Gomez@GomezDLeonMD·
Blinatumomab is effective even if given for <28 days in patients with MRD+ ALL. How long do you actually need it? Surprise! We don’t know. No one knows. In adults we do 7 days based on a Chinese study and it works fine! #Tandem26 #BMTsm #CARTcells
Andres Gomez tweet media
English
3
12
40
3.7K
Nature Medicine
Nature Medicine@NatureMedicine·
A Bayesian analysis of diagnostic data reported to the WHO reveals that approximately 2 million people were incorrectly diagnosed with tuberculosis (received a false-positive result) and 1 million received a false-negative result, emphasizing the critical need for higher-sensitivity bacteriological tests in the future. nature.com/articles/s4159…
English
4
11
40
10K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Jordan Gauthier
Jordan Gauthier@drjgauthier·
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0: 📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades. 🧪 Neutrophils: Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded. Stricter G4: threshold drops from <500 to <100/mm³. 🩸 Platelets (Thrombocytopenia): Wider G3: Now covers 10k–50k (previously 25k–50k). Stricter G4: threshold drops from <25k to <10k/mm³. v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria. Overall, IMO these new thresholds align better with clinical practice. #ClinicalTrials #MedEd #OncTwitter #DrugSafety
Jordan Gauthier tweet media
English
3
106
199
24.4K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Nitin Jain
Nitin Jain@NitinJainMD·
👉Delighted to share case series of pts with ABL class fusion ALL who received TKI with frontline Rx for ALL.Notably all 9 patients remain in CR1. 👉 Highlights need for early identification of kinase sensitive fusion and initiation of TKI @BraishJulie @MDAndersonNews Link👇
Nitin Jain tweet mediaNitin Jain tweet media
English
3
18
60
4.5K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Dr.Rachit Khandelwal, MD
Dr.Rachit Khandelwal, MD@dr_khandelwal99·
Bone Marrow Transplantation for Sickle Cell Disease: A Study of Parents' Decisions: New England Journal of Medicine: Vol 325, No 19 1991 NEJM study found that 54% of parents of kids with sickle cell disease were willing to accept a 15% mortality risk from bone marrow transplant to achieve a cure. @Satyayadav__ #SickleCell #BMT nejm.org/doi/full/10.10…
English
0
1
11
388
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Goutham Sunny
Goutham Sunny@medoncodoc·
🧬✨ ATRA Goes Beyond APL! 🔬💊 All-trans retinoic acid (ATRA), the vitamin A derivative that cured APL by reactivating differentiation in leukemic blasts, is now stepping into non-APL AML 🧠🔥 🧱 In a new twist, ATRA doesn’t target blasts directly—but instead acts on the bone marrow niche! Specifically: ➡️ Targets osteoblasts with activated β-catenin ➡️ Induces proteasomal degradation of β-catenin (GSK3-independent) 🚫🧬 ➡️ Suppresses JAG1-Notch1 signaling that fuels AML 🚷📉 🧪 In mouse models & primary AML samples, this niche-targeting effect showed promise—especially in ~40% of AMLs with active β-catenin in osteoblasts. 👨‍⚕️ Clinical highlight: An AML patient resistant to azacitidine + venetoclax achieved CR after ATRA was added. 💥 🔍 Ongoing trials (Germany 🇩🇪 & China 🇨🇳) are evaluating ATRA + HMA ± venetoclax in front-line AML. 💡Takeaway: ATRA may be repurposed as a non-cytotoxic, niche-targeting agent in AML, reviving the relevance of retinoids in modern oncology. Solid tumors like pancreatic cancer may be next! 🍊🧪🧱 doi.org/10.1016/j.ccel… @TalhaBadarMD @NitinJainMD @Daver_Leukemia @DrHKantarjian @doctorpemm @jayastuMD @GCC_Cortes @bose_prithviraj @RaajitRampal @Alkalidr @PratzKW @davidsteensma @Dr_AmerZeidan @drsangeetmd @lane_andy @CarrawayHetty @nihardesai89 @akhilrk1989 @mithunap11 @chepsyphilip @pb10_bmt @vishvdeepkhush @udaypkulkarni @DrArunCMC @Fadihaddad_MD @AuclairDan
Goutham Sunny tweet media
English
1
36
94
8.1K
Real Doc Speaks
Real Doc Speaks@realdocspeaks·
There has been an explosion in imaging in medicine. General surgeons used to make the diagnoses of appendicitis based on history, physical exam, labs and clinical judgement. Now the surgeons need a CT to make the diagnoses of appendicitis for them. Few patients get out of the ER without a CT. But the residency spots for radiology didn't increase as quickly as the scans. Add to this the explosion in the use of interventinal radiology and you have a real crisis.
English
23
8
68
15.4K
Zeal Shah 🇮🇳
Zeal Shah 🇮🇳@zeal1992·
Bought joy today in perfection, also in perspective.
Met a family from Porbandar. The son doesn’t go to school, they move town to town just to survive. We complain over silly things.
Truth is, God’s been kind.
Share your privilege or at least, don’t waste it complaining.
Zeal Shah 🇮🇳 tweet mediaZeal Shah 🇮🇳 tweet media
English
1
0
6
256
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Gaurav Narula MD
Gaurav Narula MD@DrGauravNarula·
Out now, our bit for Low Dose ImmunoRx #LoDoNiv in relapse/refractory Ped Classic Hodgkin cHL #PHLDMG @TataMemorial Fixed #LoDoNiv 40mg + Benda -> 88%CR Will now be prospective multicenter @INPHOG study @pho_india Excellent work @Dr_Shyam_S @DHCA11 & rising star @DrAditya1996
Aditya Narayan@DrAditya1996

🚨 New study alert! @Dr_Shyam_S @DrGauravNarula @DHCA11 Using fixed low-dose nivolumab (40mg D1 & D15; ~1.2mg/kg) + bendamustine, we achieved 88% CR after 2 cycles in high-risk pediatric rrHL. Full article: doi.org/10.1111/bjh.20… #PedsOnc #HodgkinLymphoma #Immunotherapy

English
0
7
40
2.2K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Anthony DiGiorgio, DO, MHA
Anthony DiGiorgio, DO, MHA@DrDiGiorgio·
At many large institutions, it’s now common for nurses to have the authority to question, and sometimes override, physician decisions. This isn’t inherently a bad thing. Patient safety should always come first, and questioning orders when there's a genuine concern should be encouraged. But balance matters. A flight attendant doesn’t knock on the cockpit door every 10 minutes to make sure the pilot really wants to follow that flight path. Trust and role clarity are essential to any high-functioning team. What’s more troubling is the asymmetry of authority. Nurses are empowered to second-guess physicians, but they’re restricted from exercising basic clinical judgment. They can challenge a medication decision, but can’t give Tylenol at midnight without a physician logging into the EMR. They can raise concerns about a diet, but can’t update a diet order themselves. They’re trusted to question, but not to act. Meanwhile, physicians bear all the liability, all the documentation burden, and all the bureaucratic clicks, yet their authority is increasingly undermined. Responsibility without authority is a recipe for burnout. And ultimately, for worse care.
Anthony DiGiorgio, DO, MHA@DrDiGiorgio

Life at a big hospital system, from a colleague: Medically complex postoperative patient was admitted to the neuro-icu. Both neuro icu and medical icu teams agreed the patient would be better served in the medical icu. The charge nurse then proceeds to block the transfer.

English
24
19
206
27.8K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Gaurav Prakash M.D.
Gaurav Prakash M.D.@DrGPrakash·
and what is a high resolution typing? (5/7)
Gaurav Prakash M.D. tweet media
English
1
2
24
1.8K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Satya Prakash Yadav
Satya Prakash Yadav@Satyayadav__·
Checkpoint inhibitors checkmate solid tumors having genetic Mismatch repair deficiency Nonoperative Management of Mismatch Repair–Deficient Tumors nejm.org/doi/full/10.10…
English
0
2
8
506
Gujarat History
Gujarat History@GujaratHistory·
GUJARATI URNAMES:- Professionalsurnames: Soni, Darji, Luhar, Suthar, Salat, Mistri, Kandoi, Sukhadia, Kadia, Vanand, Hajam, Khalasi, Malam, Tandel, Machhi, Dhobi, Kansara, Vahanvati, Kagdi, Kagzi, Darugar, Kalal, Chunara, Bhisti, Pakhali, Doshi, Tamboli, Bhoi, Bharvad, Gandhi, Modi, Dalal, Shrof, Vaidya, Vakil, Ghanchi, Kachhia, Bhadbhunja, Vankar, Dabgar, Chundrigar, Chudigar, Maniar, Kasai, Chhapia, Vakharia, Bakshi, Nanavati, Poojari, Writer, Mehta, Broker, Sodagar & many more. Gujarati surnames from state service designation: Diwan, Pradhan, Mantri, Mazumdar, Patel, Kamdar, Kazi, Bakshi, Kothari, Talati, Munshi, Mehta, Sevak, Sipahi, etc. Specific Gujarati surnames: Machchhar, Mankad, Mankodi, Ghoda, Hathi, Vagh, Sinh, Shiyal, Varu, Kag, Hans, Bakariwala, Untwala, etc. Many Gujarati surnames are formed from their ancestors' village/town/area, e.g. Patan-Patania/Patani, Champaner-Champaneria, Pavagadh-Pavagadhi, Bharuch-Bharucha, Khambhat-Khambhata, Vadodara-Vadodaria, Surat-Surati, Dholaka-Dholkia, Chhanya-Chhaya, Modhvada-Modhvadia, Kutch-Kachchhi, etc. Many Gujarati surnames are formed by the suffix 'ni' to their ancestor's name. 'Ni' means 'of ', e.g. Lakhani, Devani, Rajani, Khetani, Ramani, Kanani, Premani, Nathwani, etc. Many Gujarati surnames are formed by the suffix 'ja' to their ancestor/dynasty name. 'Ja' means 'of ' e.g. Jadeja (of Jada), Sameja (of Sama), Juneja (of Juna). Many Gujarati surnames are formed by the suffix 'wala' to thing/city.'wala' means related to/trader of, e.g. Rangoonwala, Poonawala, Daruwala, Khandwala, Masharuwala, etc. Brahmins' surnames showing their ancestors' knowledge of Veda & Purana: Ved (1 Ved knowledge), Dwivedi (2 Ved), Trivedi (3 Ved), Chaturvedi (4 Ved) & Purani.Professional surnames of Brahmin & Nagar of Gujarat: Yagnik, Jani, Acharya, Agnihotri, Joshi, Mehta, Upadhyay, Vaidya, Sevak, etc. Artisans, O.B.C. & S.C. of Gujarat adopted Rajput surnames such as Solanki, Rathod, Parmar, Chauhan, Chavda, Vaghela, Zala, Gohil, Jethwa, Vala, Rana, etc to show/indicate the dynasty of their Rajput ruler whoe they were subject of OR Rajputs' marriages with them in ancient time.
Gujarat History tweet mediaGujarat History tweet mediaGujarat History tweet mediaGujarat History tweet media
Indonesia
8
18
144
6.1K
Ravi Shah MBBS, MD 🇮🇳🇨🇦 retweetledi
Dr. Chokri Ben Lamine
Dr. Chokri Ben Lamine@abouabdrahman0·
Intrathecal MTX Prophylaxis 💉🧠 in DLBCL: No Impact on Parenchymal CNS Relapse •Key Point: Most CNS relapses in DLBCL are parenchymal, not leptomeningeal •Implication: IT chemotherapy alone (e.g., MTX) doesn’t prevent CNS relapse •Multiple trials confirm: •RICOVER-60: 6.9% vs 4.1% (no benefit with rituximab) •Tai et al: 18% CNS relapse despite IT •Schmitz et al: No CNS benefit •GOYA / UK NCRI / NCCN datasets: consistent lack of efficacy in CNS relapse prevention •Why? •IT chemo distributes in CSF → targets leptomeninges •Parenchymal CNS involvement needs systemic high-dose MTX or CNS-penetrant agents •Takeaway: •Do not rely solely on IT MTX for CNS prophylaxis in high-risk DLBCL •Consider HD-MTX or systemic CNS-directed therapy in select high-risk patients 🧠🔥 #DLBCL #CNSRelapse #Hematology #Oncology #ASH2024 #CNSProphylaxis #HighRiskDLBCL
Dr. Chokri Ben Lamine tweet media
English
2
9
44
2.2K